Jayne Brockhaus
Family Medicine · Warrensburg, MONPI 1427005925
Payments from drug & device makers
Across 561 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$2K
- AstraZeneca$1K
- Lilly USA, LLC$959
- Novo Nordisk$767
- Dexcom, Inc.$547
- plus $5K from 50 others
What the payments were for
- Travel & lodging$200%
- Food & beverage$11,929100%
- Education$350%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$604
- t:slim X2 Insulin Pump with Control-IQ$370
- AIRSUPRA$230
- Otezla$221
- AIMOVIG$209
- MINIMED 780G$154
- DEXCOM G7 GSS (161)$149
- FARXIGA$126
- BOTOX$123
- VRAYLAR$118
- REXULTI$106
- AJOVY$103
- BREZTRI$103
How this compares
$11,984 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 82 | $98,948 |
| FarxigaDapagliflozin Propanediol | 72 | $78,548 |
| EliquisApixaban | 82 | $63,475 |
| JardianceEmpagliflozin | 42 | $62,490 |
| MyrbetriqMirabegron | 45 | $37,431 |
| Repatha SyringeEvolocumab | 21 | $26,680 |
| TrulicityDulaglutide | 16 | $21,558 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $16,406 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $16,008 |
| LinzessLinaclotide | 15 | $14,876 |
| MounjaroTirzepatide | 12 | $13,259 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $12,894 |
| EntrestoSacubitril/Valsartan | 16 | $12,001 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $10,349 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $9,788 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $767 | $98,94882 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,386 | $94,95490 claims |
| PfizerEliquis, Abrysvo | $405 | $67,95797 claims |
| Boehringer IngelheimJardiance | $183 | $62,49042 claims |
| Astellas Pharma US IncMyrbetriq | $64 | $37,43145 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $959 | $34,81728 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $128 | $28,93868 claims |
| AbbVieLinzess | $1,786 | $14,87615 claims |
| NovartisEntresto | $342 | $12,00116 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $365 | $1,72715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Warrensburg
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.